Opinion|Videos|October 28, 2024
Incorporating Real-World Evidence for HER2+ NSCLC
Key Takeaways
- Real-world evidence enhances understanding of HER2-directed therapies' effectiveness and safety in diverse populations, complementing clinical trial data.
- Collaboration among payers, providers, and manufacturers is vital for equitable access to HER2-directed therapies and cost management.
Panelists discuss how real-world evidence plays a crucial role in shaping both clinical decision-making and coverage policies for HER2-directed therapies in NSCLC, while exploring collaborative strategies between payers, providers, and manufacturers to balance equitable access with cost management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role do you see for real-world evidence in informing both clinical decision-making and coverage policies for HER2-directed therapies?
- (Heymach) How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Trump Childhood Vaccine Order: What It Means for Parents and Payers
2
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
3
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
4
OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs
5